What is One Drop?
Founded in 2015 and headquartered in New York City, One Drop leverages mobile computing and data science to provide a comprehensive diabetes management platform. The service allows individuals to log daily activities, including food intake, insulin levels, and exercise, enabling them to visualize the intricate relationships between these factors and their glucose levels. This data-driven approach empowers users to better understand and manage their condition, positioning One Drop as a key player in the digital therapeutics and chronic disease management market.
How much funding has One Drop raised?
One Drop has raised a total of $154.4M across 6 funding rounds:
Angel/Seed
$1M
Series A
$8.6M
Private Equity
$6.1M
Series B
$40M
Corporate Investment
$64M
Series C
$34.7M
Angel/Seed (2015): $1M, investors not publicly disclosed
Series A (2015): $8.6M led by Box Group, RRE Ventures LLC., Capital Factory companies, Launch, and Neulogy Ventures
Private Equity (2017): $6.1M, investors not publicly disclosed
Series B (2019): $40M featuring Bayer
Corporate Investment (2020): $64M backed by Bayer
Series C (2020): $34.7M with participation from Bayer
Key Investors in One Drop
Bayer
Bayer, a global life science enterprise with divisions in pharmaceuticals and consumer health, has participated in One Drop's funding rounds, indicating a strategic interest in digital health solutions for chronic disease management.
Box Group
BoxGroup is an early-stage investment fund focused on technology companies, including those in the health tech sector, suggesting a focus on innovative startups with high growth potential.
RRE Ventures LLC.
RRE Ventures is a venture capital firm dedicated to supporting founders at critical stages, likely investing in One Drop for its innovative approach to diabetes management and its potential for market disruption.
What's next for One Drop?
With the recent influx of major strategic investment, One Drop is poised for accelerated growth and innovation. The company is likely to focus on enhancing its data analytics capabilities, expanding its user base, and potentially forging new partnerships within the healthcare ecosystem. This substantial backing suggests a strong investor confidence in One Drop's business model and its potential to significantly impact diabetes care through technology. Future developments may include expanding service offerings, integrating with more healthcare providers, and further refining its predictive analytics for personalized health insights.
See full One Drop company page
